Two targeted drugs for advanced EGFR-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of two targeted drugs (andamertinib and anlotinib) for lung cancer that has EGFR mutations and has progressed after a prior EGFR TKI. It aims to see if the combination can shrink tumors and help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a type of lung cancer called non-small cell lung cancer that has spread or cannot be removed with surgery.
- Your cancer has a specific genetic change called EGFR (like an exon 19 deletion or L858R mutation).
- You have already been treated with a third-generation EGFR TKI (like osimertinib) and it stopped working.
- You have at least one tumor that can be measured on a scan.
- You are able to do your daily activities without significant help (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial tests two drugs (luvometinib and anlotinib) together to treat advanced lung cancer that has a KRAS mutation and has grown despite previous treatment. The goal is to see if this combination helps patients live longer and slows cancer growth.
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
This Phase 2 study tests two targeted medicines together (aumolertinib plus anlotinib) as first treatment for advanced lung cancer with specific gene changes (EGFR 19del or L858R plus TP53). It aims to see whether the combination is effective and safe when starting treatment.
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
Hear when a new Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.